rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

NCT03829449 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped The early termination of this study is a business decision, Akari have made the decision to close their global Phase III PNH program. The decision was not related to any efficacy, safety or clinical concerns regarding Coversin/rVA576.

Conditions

Interventions

Sponsor

AKARI Therapeutics